Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ming-Tain Lai | Chief Scientific Officer | 7.73M | -- | -- |
| Dr. Heidi Wang Ph.D. | Chief Executive Officer | -- | -- | -- |
| Mr. Colin Kao | CFO, Accounting Supervisor & Corporate Governance Supervisor | -- | -- | -- |
| Mr. Po-Jen Chang | Director of Human Resources & Administration | -- | -- | -- |
| Ms. Sharon Lee | Director of Public Affairs | -- | -- | -- |
| Mr. Kevin P. Poulos | Chief Business Officer of OBI Pharma USA, Inc. | -- | -- | 1959 |
| Dr. Wayne Saville M.D. | Chief Medical Officer of OBI Pharma USA, Inc. | -- | -- | -- |
| Dr. Dong Xu Ph.D. | Senior Vice President of Biostatistics & Data Management of OBI Pharma USA, Inc. | -- | -- | -- |
| Mr. Chun-Hung Chou | Vice President of Chemical Pharmacy and R&D Office | -- | -- | -- |
OBI Pharma, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor surface antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a Globo H monoclonal antibody; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898, OBI-998, and COVID-19 BCVax drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.
Corporate Governance
Upcoming Events
March 10, 2025 at 10:59 AM UTC - March 14, 2025 at 12:00 PM UTC
OBI Pharma, Inc. Earnings Date
Recent Events
Recent Events Information Not Available